medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 1

<< Back Next >>

Acta Med 2021; 19 (1)

Immune checkpoint inhibitors in advanced stages of melanoma

Tamariz CAF, Corona DA, Mellado OR, Díaz GEJ, Rodríguez WFL

Language: Spanish
References: 42
Page: 108-115
PDF size: 196.40 Kb.


ABSTRACT

Melanoma is the type of skin cancer with highest mortality worldwide due to its metastatic potential. In the recent years there has been an increasing incidence of melanoma worldwide, including in Mexico. There are several mechanisms involved in the pathogenesis of melanoma making it difficult to develop specific therapies. However, recently immunotherapy has been taking interest in treatment of melanoma, due to the introduction of inhibitors of immune checkpoints, this type of therapy has significantly improved long-term survival in patients with advanced melanoma. Therefore, the scientific community has focused on comparing side effects and efficacy versus standardized treatments, until today no better outcomes have been found, on the contrary patients can present an immune related response due to their action mechanism. Unfortunately, only a few patients have shown a satisfactory response to this type of therapy. This article reviews the results of the most recent studies conducted with checkpoint inhibitors, recommended doses, and frequency of adverse effects on immune system.


REFERENCES

  1. Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012; 22 (2): 114-122.

  2. Gershenwald JE, Guy GP Jr. Stemming the rising incidence of melanoma: calling prevention to action. J Natl Cancer Inst. 2015; 108 (1): djv381.

  3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80 (6): 827-841.

  4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127 (12): 2893-2917.

  5. Melanoma Skin Cancer Statistics [Internet]. Cancer.org. 2020 [cited 17 April 2020]. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html

  6. Global Cancer Observatory [Internet]. Gco.iarc.fr. 2018 [cited 17 April 2020]. Available from: http://gco.iarc.fr/

  7. Martínez SH. El primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol. 2005; 4 (2): 11-13.

  8. Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. Development. 2015; 142 (4): 620-632.

  9. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014; 9: 239-271.

  10. Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A et al. Melanoma. Nat Rev Dis Primers. 2015; 1: 15003.

  11. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014; 383 (9919): 816-827.

  12. Hawryluk EB, Tsao H. Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med. 2014; 4 (9): a015388.

  13. Ward KA, Lazovich D, Hordinsky MK. Germline melanoma susceptibility and prognostic genes: a review of the literature. J Am Acad Dermatol. 2012; 67 (5): 1055-1067.

  14. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell. 2012; 150 (2): 251-263.

  15. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339 (6122): 957-959.

  16. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339 (6122): 959-961.

  17. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44 (9): 1006-1014.

  18. Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016; 16 (6): 345-358.

  19. Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020; 100 (1): 1-12.

  20. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V et al. A review of human carcinogens--part D: radiation. Lancet Oncol. 2009; 10 (8): 751-752.

  21. IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. IARC Monogr Eval Carcinog Risks Hum. 1992; 55: 1-316.

  22. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009; 60 (6): 1001-1017.

  23. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014; 28 (6): 1005-1011.

  24. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007; 82 (3): 364-380.

  25. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005; 41 (1): 28-44.

  26. Goldman L, Schafer AI. Goldman-Cecil medicine. 26th ed. Philadelphia, PA: Elsevier/Saunders; 2019. 2 volumes (xl, 2722, I108 pages).

  27. Cancer Statistics Review, 1975-2013-Previous Version-SEER Cancer Statistics Review [Internet]. SEER. 2020 [cited 17 April 2020]. Available from: https://seer.cancer.gov/archive/csr/1975_2013/.

  28. Melanoma of the Skin-Cancer Stat Facts [Internet]. SEER. 2020 [cited 17 April 2020]. Available from: https://seer.cancer.gov/statfacts/html/melan.html

  29. Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. Brisbane (AU): Codon Publications; 2017. doi: 10.15586/codon.cutaneousmelanoma.2017

  30. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723.

  31. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364 (26): 2517-2526.

  32. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016; 375 (19): 1845-1855.

  33. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33 (28): 3193-3198.

  34. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16 (4): 375-384.

  35. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372 (4): 320-330.

  36. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377 (19): 1824-1835.

  37. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373 (1): 23-34.

  38. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16 (8): 908-918.

  39. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019; 381 (16): 1535-1546.

  40. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372 (26): 2521-2532.

  41. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018; 378 (19): 1789-1801.

  42. Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM et al. Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. JAMA Netw Open. 2020; 3 (3): e201611.




2020     |     www.medigraphic.com